Table 1.
Documentation codes for Pneumococcal vaccination (G-BA, 2020) [14].
Table 2.
Immunocompromised patient characteristics with a first diagnosis of a condition for which pneumococcal vaccination is recommended as per STIKO guidelines.
Fig 1.
Selection of patient populations for cohorts A and B.
Table 3.
Pneumococcal vaccination rates with 95% CI within two years following diagnosis of immunocompromised condition.
Table 4.
Physician administering the vaccination in each cohort.
Table 5.
Vaccination rates (with 95% CI) by physician specialty first diagnosing the incident immunocompromised condition putting patient at high-risk for pneumococcal disease.
Fig 2.
Cumulative pneumococcal vaccination rate within eight quarters after first documented immunocompromised condition by cohort.
Fig 3.
Time (in days) following a first vaccination to a sequential in a 15-month period in cohort B.
Patients aged 16–59 (upper and lower 95% CI) compared to patients aged ≥60 years (upper and lower 95% CI) patients (see S4 Table in supplemental material for 95% CIs).
Table 6.
% of patients with a sequential vaccination following a first vaccination to a sequential vaccination in a 15-month period in cohort B patients aged 16–59 (upper and lower 95% CI) and ≥60 years (upper and lower 95% CI).